1429 related articles for article (PubMed ID: 15051039)
21. Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells.
Zhu XQ; Lv JQ; Lin Y; Xiang M; Gao BH; Shi YF
Gynecol Oncol; 2007 Jun; 105(3):650-6. PubMed ID: 17368523
[TBL] [Abstract][Full Text] [Related]
22. Expression of the O-linked N-acetylglucosamine containing epitope H in normal myometrium and uterine smooth muscle cell tumors.
Sgantzos MN; Galani V; Arvanitis LD; Charchanti A; Psathas P; Nakou M; Havaki S; Kallioras V; Marinos E; Vamvakopoulos NC; Kittas C
Pathol Res Pract; 2007; 203(1):31-7. PubMed ID: 17129677
[TBL] [Abstract][Full Text] [Related]
23. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins.
Amada S; Nakano H; Tsuneyoshi M
Int J Gynecol Pathol; 1995 Apr; 14(2):134-42. PubMed ID: 8601525
[TBL] [Abstract][Full Text] [Related]
24. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.
Zhai YL; Nikaido T; Toki T; Shiozawa A; Orii A; Fujii S
Br J Cancer; 1999 Jul; 80(10):1658-64. PubMed ID: 10408415
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of the ERα/ERβ ratio and neurotensin and its high-affinity receptor in myometrium, uterine leiomyoma, atypical leiomyoma, and leiomyosarcoma.
Rodríguez Y; Báez D; de Oca FM; García C; Dorta I; Reyes R; Valladares F; Almeida TA; Bello AR
Int J Gynecol Pathol; 2011 Jul; 30(4):354-63. PubMed ID: 21623207
[TBL] [Abstract][Full Text] [Related]
27. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
28. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
29. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
30. [Histological diagnosis and clinical features in borderline smooth muscle tumors of the uterus].
Shi YF; Xie X; Zhao CL
Zhonghua Fu Chan Ke Za Zhi; 1994 Apr; 29(4):201-4, 251. PubMed ID: 8082439
[TBL] [Abstract][Full Text] [Related]
31. Bcl-2 expression and other clinicopathologic parameters in uterine leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
Wien Klin Wochenschr; 2004 Feb; 116(4):135-9. PubMed ID: 15038405
[TBL] [Abstract][Full Text] [Related]
32. Molecular analyses of 6 different types of uterine smooth muscle tumors: Emphasis in atypical leiomyoma.
Zhang Q; Ubago J; Li L; Guo H; Liu Y; Qiang W; Kim JJ; Kong B; Wei JJ
Cancer; 2014 Oct; 120(20):3165-77. PubMed ID: 24986214
[TBL] [Abstract][Full Text] [Related]
33. Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis.
Comunoğlu NU; Durak H; Comunoğlu C; Ekici AI; Ozkan F; Akyildiz EU; Ilvan S; Calay Z; Molinas N
APMIS; 2007 Jun; 115(6):726-35. PubMed ID: 17550381
[TBL] [Abstract][Full Text] [Related]
34. Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
Ip PP; Tse KY; Tam KF
Adv Anat Pathol; 2010 Mar; 17(2):91-112. PubMed ID: 20179432
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.
Hewedi IH; Radwan NA; Shash LS
Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth factor-alpha, epidermal growth factor receptor, and PCNA immunoexpression in uterine leiomyosarcomas and leiomyomas in B6C3F1 mice.
Moore AB; He H; Yoshida A; Rico PJ; Haseman JK; Dixon D
Exp Toxicol Pathol; 2000 Jun; 52(3):195-200. PubMed ID: 10930119
[TBL] [Abstract][Full Text] [Related]
37. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus.
Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F
Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545
[TBL] [Abstract][Full Text] [Related]
38. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
39. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling.
Quade BJ; Wang TY; Sornberger K; Dal Cin P; Mutter GL; Morton CC
Genes Chromosomes Cancer; 2004 Jun; 40(2):97-108. PubMed ID: 15101043
[TBL] [Abstract][Full Text] [Related]
40. Reduced expression of calponin h1 in leiomyosarcoma of the uterus.
Horiuchi A; Nikaido T; Ito K; Zhai Y; Orii A; Taniguchi S; Toki T; Fujii S
Lab Invest; 1998 Jul; 78(7):839-46. PubMed ID: 9690561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
